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Specific protocols define eligibility, conditioning, donor selection, graft composition
and prophylaxis of graft vs. host disease for children and young adults undergoing
hematopoietic stem cell transplant (HSCT). However, international protocols rarely, if ever,
detail supportive care, including pharmaceutical infection prophylaxis, physical protection
with face masks and cohort isolation or food restrictions. Supportive care suffers from
a lack of scientific evidence and implementation of practices in the transplant centers
brings extensive restrictions to the child’s and family’s daily life after HSCT. Therefore,
the Board of the Pediatric Diseases Working Party (PDWP) of the European Society for
Blood and Marrow Transplantation (EBMT) held a series of dedicated workshops since
2017 with the aim of initiating the production of a set of minimal recommendations. The
present paper describes the consensus reached within the field of infection prophylaxis.
Keywords: infection precaution, allogeneic hematological stem cell transplantation, children, antibiotic
prophylactic therapy, vaccination
INTRODUCTION
Infectious complications are a major cause of morbidity and
mortality in children undergoing hematopoietic stem cell
transplantation (HSCT). In the early history of HSCT many
patients died due to reactivated viruses of the herpes family
and de novo infections especially by fungi and respiratory
viruses. Modern HSCT programs therefore rely heavily on
efficient infection prevention and early treatment of infections
to continue the significant improvement in transplant related
mortality (TRM) experienced during the past decades.
Measures to avoid exposure to infectious pathogens include
amongst others cohort isolation, use of physical barriers,
pharmaceutical prophylaxis, food restriction and vaccinations. In
order to help the families and health care workers on how to
manage infection risk, local supportive care guidelines are issued
in most HSCT centers. However, such guidelines are often based
on local preferences rather than on evidence-based studies due
to difficulties of carrying out controlled studies in this field. Yet,
comprehensive international guidelines were published in 2009
for non-pharmacologic infection prevention during HSCT. The
guidelines included the use of HEPA filtered rooms, isolation
precautions, restriction of certain food items and crowd isolation
(1, 2). Recently, such general recommendations were reviewed in
the 2019 handbook issued by the European Society for Blood and
Marrow Transplantation (EBMT) (3).
In order to provide an updated and comprehensive set of
recommendations directed specifically for children and young
adults, the Board of the Pediatric Diseases Working Party
(PDWP) of the EBMT decided to review the current evidence
within infection prevention in children, during the work on
supportive care in pediatric HSCT.
The work was based on repeated focused meetings of the
board of PDWP and experts within the fields of pediatric HSCT:
Different topics on supportive care were each prepared and
finalized by a sub-committee within a total of three meetings
held between October 2017 and November 2018 as detailed in
the initial paper by Nava et al. (4). Briefly, prior to the initial
meeting experts from each sub-committee reviewed the literature
and presented during the first meeting a list of issues to be
addressed and a draft proposal for the structure and major
content of a consensus statement. Based on thorough discussions
within the sub-committee and then the entire group, the major
objectives/topics and most substantial pieces of evidence but also
uncertainties were identified and formed the basis for discussing
a more detailed consensus recommendation during the second
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meeting. During the third meeting the final recommendations
were agreed upon within each sub-committee and in consensus
of all workshop attendants.
The current publication is the 3rd volume following these
supportive care workshops and presents the consensus of
infection prevention in pediatric HSCT recipients with a special
focus on an updated vaccination program and guidelines for
restrictions following discharge until full de-isolation. Following
re-evaluation with two further virtual meetings in April 2020
and February 2021, the manuscript also includes considerations
regarding Coronavirus disease 2019 (COVID-19).
PROTECTIVE MEASURES AT THE HSCT
WARD
In general, it is recommended to reduce all risks of community
acquired infections. The level of inpatient isolation varies
between centers due to local logistics and priorities but also due to
lack of evidence of specific actions. We here provide the updated
recommendations based on international guidelines (1, 2, 5–8)
and on the practice in the highly specialized pediatric EBMT
centers involved in the workshops. Recently, specific guidelines
for SARS-CoV-2 prevention and control have been worked out
by scientific societies, including the EBMT (9).
Rooms
Allo-HSCT recipients should be treated in a highly shielded
environment with single patient rooms, preferentially with HEPA
filters for prevention of airborne fungal infections, especially
Aspergillus (1). Filters should be replaced regularly according to
the manufacturer’s recommendations, especially in centers with
ongoing construction work (10, 11). There should be at least 12
air exchanges per hour, keeping a consistent positive air pressure
of at least 2.5 Pa between the patient room and hallway (1, 12). In
case of a recipient affected with disease transmissible by droplets
(i.e., COVID-19, measles), a switch to negative pressure might be
considered, in order to protect the ward.
Barrier Precautions
When entering and leaving the room and before and after
patient contact, hand hygiene including alcohol-based hand
rubs/hand washing with soap (plain or antimicrobial) and water
is absolutely essential (13, 14). In the absence of visible soiling
of hands or potential contact with spore-forming organisms
(e.g., Clostridium difficile), alcohol-based hand rub can be used.
Rings, bracelets, artificial nails and adhesive bandages should
be avoided. Personal protective equipment (gloves, masks, and
gowns) should be worn during procedures generating splashes
of body fluids or causing soiling of clothes. Additionally, when
indicated on the basis of coexisting conditions, patients should
be placed on airborne, droplet or contact precautions (7). Toys
including games, videos, mobile phones, and tablet computers
should be wiped with certified cleansing material before being
brought into the room and thereafter at least once weekly
(15–17). Plants, dried or fresh flowers are prohibited. Each
patient should have designated examination tools and routine
examination equipment should not be transferred from room
to room.
Health Care Workers and Visitors
All HCWs should be vaccinated according to national guidelines
including annual influenza vaccination (18). A HCW with
known or suspected transmissible infection should have no
direct contact with the patients or other HCW and if possible,
should be temporarily referred to back-office tasks, or in the
case of COVID19 pandemic stay home according to guidelines
(19). Visitors should be restricted to as few as possible and
any showing signs of infection should be excluded from the
transplant unit and from direct contact with HSCT recipients or
candidates undergoing conditioning therapy until all symptoms
have resolved (1). No absolute minimum age for visitors can be
recommended, some centers accept visitors older than 12 years
old including siblings, whereas other centers accept even younger
visitors. All visitors, including children must be able to follow
strict hand hygiene and isolation precautions. Furthermore,
during the COVID-19 pandemic, strict adherence to masks
by staff and visitors must be followed. Visitor restrictions to
transplant units often imply one parent only following negative
SARS-CoV-2 testing. The visit of the second parent is rarely
allowed, except in case of end-of-life situations.
Given the suboptimal immunogenicity in HSCT patients,
family members and healthcare professionals involved in the
care of these populations should be vaccinated during influenza
seasons, prior to and at least 12 months after HSCT, till
patients are able to get and respond efficiently to vaccination.




Enteral nutrition is generally encouraged in order to preserve
the natural microbiota, thus reducing the risk of graft vs. host
disease (GvHD) and possibly the speed of platelet recovery (20).
Conditioning-associated nausea and mucositis generally leads to
a reduction in the appetite and oral food intake during HSCT,
especially during the neutropenic phase (4). Traditionally, certain
dietary items have been widely restricted to reduce the risk of
introducing harmful food-borne microorganisms to the HSCT
patient (“neutropenic diet”), which is increasingly questioned.
A retrospective study analyzed infectious complications in 726
consecutive adult HSCT recipients, 25% receiving an allogeneic
transplant (21). A neutropenic diet was provided to 363
patients who underwent HSCT between 2004 and 2006, whereas
363 patients undergoing HSCT after 2006 did not receive a
neutropenic diet. The only significant difference between the
groups was a higher number of microbiologically documented
infections after resolution of neutropenia in patients receiving
neutropenic diet. A small prospective and randomized pilot study
compared a total of 46 adult patients receiving neutropenic
diet or a diet without restrictions from day 1 of conditioning
until engraftment and did not find differences in infections
(22), which corroborates the results of a meta-analysis including
1,116 patients, with 772 (69.1%) having undergone HSCT (23).
Unfortunately, data of the effect of a neutropenic diet in pediatric
HSCT is lacking to date, but, superiority of a strict neutropenic
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TABLE 1 | Handling of food items during allogeneic hematopoietic cell transplantation.
Steps Handling and preparing food items Selecting the lower risk option of food items
Low risk High risk
Clean Wash hands and surfaces often.
Rinse fruits and vegetables, and rub firm-skin fruits and vegetables under
running tap water.
Washed fresh vegetables including
lettuce/salads; cooked vegetables
Unwashed fresh vegetables including
lettuce/salads
Separate Separate raw meat, poultry, seafood, and eggs from other foods to avoid
cross-contamination (e.g., in the refrigerator, using different cutting boards
for raw foods and ready-to-eat food).
Cook Cook to safe temperatures, consider using a food thermometer to measure
the internal temperature (e.g., beef, lamb, pork, veal and fish to at least
63◦C, ground meat to at least 70◦C, eggs until yolks and whites are firm).
Reheat hot dogs and luncheon meats until steaming hot or 75◦C.
Sufficiently cooked meat, poultry,
seafood and eggs; canned fish and
seafood; pasteurized milk, milk
products, egg and egg products
Raw or undercooked meat, poultry,
seafood; unpasteurized (raw) milk and
milk products
Hot dogs and luncheon meats that
have not been reheated
Chill Refrigerate promptly and follow cold storage charts for refrigerator (below
4◦C) and freezer (<-16◦C). Never thaw food at room temperature.
diet was not demonstrated in either adults or pediatric oncology
patients receiving chemotherapy (24–27).
There is considerable variation in practices in dietary
restrictions of specific food items between HSCT-centers (28,
29). However, the growing body of evidence of the lack of
benefit of a neutropenic diet has led to an increasing number of
cancer centers replacing the strict neutropenic diet with safe food
handling guidelines (30, 31). In this regard, the US Department
of Agriculture/FDA continues to recommend the avoidance of
uncooked groundmeat or unpasteurizedmilk andmilk products,
whilst categorizing other foods such as fresh vegetables and salad
as lower risk food permitted for cancer patients provided certain
conditions of food handling and preparation are strictly adhered
to (Table 1). Four essential steps (“clean, separate, cook and
chill”) are highlighted, and detailed recommendations regarding
washing hands and surfaces (“clean”), how to prevent cross-
contamination from one food product to another (“separate”),
how to cook different food items to safe temperatures (“cook”)
and how to refrigerate properly (“chill”) are given.
In conclusion, replacing the strict neutropenic diet in HSCT
recipients with a more palatable diet should not result in an
increased risk of infection and would improve the quality of life
and further result in an increase in oral intake of calories and
protein, helping to prevent undesirable weight loss. However,
this consensus statement of European pediatric HSCT-centers
needs to be adapted by each center according to regional and
local circumstances.
PHARMACEUTICAL MICROBIAL
PROPHYLAXIS DURING AND AFTER HSCT
Exposure to infectious pathogens is unavoidable and necessitates
antimicrobial prophylaxis during and after HSCT in all patients.
The duration of prophylaxis may depend more on the degree
of immune reconstitution in any individual patient rather
than any specific time from HSCT. Current evidence has
been reviewed and the PDWPs recommendations for the
antimicrobial prophylaxis are summarized in Table 2. Local
circumstances may modify these recommendations.
Pre-assessment
Thorough pre-HSCT assessment including virus specific
antibody titers, syphilis and toxoplasmosis is a pre-requisite for
the risk management of either reactivation or de novo infection
and can guide prophylactic treatment pre- and post-discharge.
Patients testing IgG-seronegative should in general remain
on prophylactic treatment to avoid de novo infection prior to
HSCT. Interferon-gamma-release assay (IGRA) rather than a
tuberculin skin test, is recommended if tuberculosis is clinically
suspected. Occasionally in non-acute HSCT, the time from
initial referral of the child until HSCT may allow for considering
targeted antimicrobial therapy or (re)- immunization and/or
immunoglobulin prior to transplant. Pre-transplant serology
may not be relevant for anamnestic IgG in those who were
recently exposed to products containing plasma (fresh frozen
plasma, platelet concentrates, granulocyte transfusions, . . . ) or
received intravenous immunoglobulin infusion.
Antibacterial Prophylaxis
Systemic antibacterial prophylaxis and selective gut
decontamination is no longer recommended during the
neutropenic period (32–35). Instead, immediate administration
of intravenous antibiotic treatment when infection is suspected
is mandatory. Empiric antibiotic treatment should be adapted
to local resistance patterns, patients’ colonization status and
cover gram-negative aerobic bacteria (Enterobacteriaceae and
Pseudomonas aeruginosa) and gram-positive cocci (streptococci,
Staphylococcus aureus and Enterococci). A strict implementation
of the guidelines for treatment of febrile neutropenia is
mandatory (35–37).
Late infection prevention (>100 days posttransplant),
targeting mainly encapsulated bacteria (Streptococcus
pneumoniae and Haemophilus influenzae), should include
penicillin or macrolide antibiotics during immunosuppressive
treatment for GvHD (38, 39), immunoglobulin
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TABLE 2 | Antimicrobial prophylaxis in children undergoing allogeneic hematopoietic cell transplantation.
Phase Antibacterial Antiviral Pnemocystis/toxoplasmosis Antifungal IVIG
Conditioning NGR NGR NGR NGR NGR
Pre-engraftment NGR aciclovir NGR L-AmB, azoles or echinocandins NGR
Post-engraftment w/o a/c GvHD NGR aciclovir SMX/TMP NGR NGR
Post-engraftment with a/c GvHD PNC aciclovir SMX/TMP azoles or echinocandins NGR
NGR, not generally recommended; PNC, penicillin; SMX/TMP, sulfamethoxazole/trimethoprim; L-AmB, intravenous liposomal amphotericin B; IVIG, intravenous immunoglobulin.
If IgG levels below 400 mg/dL IVIG could be given. a/c GvHD, acute or chronic graft vs host disease.
replacement therapy (i.v. or s.c.) in patients with severe
hypogammaglobulinemia (serum IgG level < 400 mg/dL) and
vaccinations (see later).
Antiviral Prophylaxis
The risk of HSV disease after allo-HSCT in the absence of
prophylaxis is ∼80%, especially during the first neutropenic
period after HSCT or associated with stomatitis. Prophylaxis
with aciclovir (ACV), at a standard dose of 2 × 20 mg/kg from
day +1 is recommended in all HSV seropositive patients until
neutrophil engraftment or mucosal recovery (3, 40). However,
the emergence of drug resistance to ACVmay hamper the efficacy
of HSV prophylaxis, thus ACV-resistant HSV isolates has been
reported in up to 30% among allogeneic bone marrow transplant
patients (41).
Following discharge, it is recommended that VZV-
seropositive patients receive ACV (2 × 20 mg/kg or 2 × 800mg
in adolescents) or valaciclovir (2 × 500mg in adolescents)
until day +365. There may be an increased risk of delayed
VZV-reactivation after discontinuing ACV (rebound) and
optimal ACV dose and duration of the prophylaxis is still
to be defined (40, 42). Post-exposure prophylaxis with anti-
VZV-immunoglobulins (within 96 h) and ACV/valaciclovir
is recommended for seronegative patients exposed to VZV.
Prophylaxis should be started as soon as possible and continued
until 21 days after exposure (43). Primary VZV-infection
after allo-HSCT is associated with a high mortality and
should be avoided by isolation measures or vaccination (2).
Cytomegalovirus (CMV) is a well-known cause of disease
occurring after allogeneic HSCT. The manifestations of CMV
range from asymptomatic infection, defined as active CMV
replication in the blood in the absence of clinical and organ
manifestations to CMV disease, characterized by CMV infection
with clinical symptoms and/or organ function abnormalities.
Fever, cytopenia, pneumonia, gastrointestinal involvement and
retinitis are the most frequent presentations. CMV prophylaxis
or pre-emptive therapy has changed the natural history of the
disease, reducing the risk of CMV disease, CMV-associated
death and transplant-related mortality.
Prevention of CMV disease is a prerequisite in allo-HSCT
and includes preference of CMV-matched donor/recipient pairs
and prevention of virus exposure by discontinuation of breast
feeding by CMV-positive mothers (44), physical protection
measures (isolation) and use of leukodepleted and/or gamma-
irradiated blood products. A preemptive strategy based on
weekly monitoring of CMV replication is strongly recommended
using foscarnet before and ganciclovir after stable neutrophil
engraftment in the presence of rising CMV-loads (45). CMV-
monitoring should continue until acceptable immune recovery
and/or tapering of immunosuppressive therapy (IST). CMV
prophylaxis with letermovir is recommended in adult CMV-
positive HSCT recipients (45) and may be an option for
seropositive children in an off-label setting (46).
Prevention of EBV-disease following HSCT relies on
prevention of exposure (isolation) and preemptive strategies
in EBV-seropositive patients (47, 48). Post-transplant
lymphoproliferative disease (PTLD) is the most frequent
EBV-associated transplant related disease. For timely diagnosis,
it is recommended to weekly monitor by quantitative PCR
until immune recovery. In case of rapidly increasing viral loads,
preemptive treatment with Rituximab is recommended (2, 49).
Rituximab-induced B cell depletion has a prophylactic role
in controlling EBV-DNAemia after HSCT. Rituximab targets
CD20+ B cells which proliferate under the viral trigger, thus
removing the EBV reservoir. However, it is not clear if rituximab
improves survival, beyond reducing EBV DNAemia. Therefore,
the latest ECIL-6 guidelines only recommend prophylactic
rituximab for patients at very high risk of developing PTLD,
with surveillance of hypogammaglobulinemia and prompt
administration of intravenous immunoglobulins to limit
rituximab-related complications (12). EBV-specific cytotoxic
T lymphocytes (CTLs) showed promising results but remain
limited to second-line settings. Antiviral agents are ineffective in
vivo since their target is not expressed by latent B cells (50).
Primary infections or reactivations of other respiratory
tract viruses (RSV, parainfluenza, influenza, and adenovirus)
are associated with severe illness and should be monitored
closely. Prevention of disease relies on preventing exposure
before and after HSCT, see below. HHV-6, parvovirus B19 and
the polyomaviruses (BK and JC) are associated with specific
clinical entities in allo-HSCT recipients. However, no established
prophylaxis exists for these and no recommendations can be
made currently (51).
Antifungal Prophylaxis
Invasive fungal infections (IFI) remain a challenge due to
substantial morbidity and mortality, despite the availability
of new antifungal drugs such as broad spectrum triazoles
or echinocandins. Primary antifungal prophylaxis is strongly
recommended irrespective of primary diagnosis during the
Frontiers in Pediatrics | www.frontiersin.org 5 July 2021 | Volume 9 | Article 705179
Ifversen et al. Minimal Recommendations on Infection Prevention
neutropenic phase and until immune reconstitution and
in situations with augmented immunosuppression due to GvHD,
which is in line with the updated guidelines according to the
Eighth Conference on Infections in Leukemia (ECIL-8) (35).
We recommend practice according to the ECIL-8 guidelines
to include fluconazole (only if the institutional incidence of
invasive mold infections is low) or voriconazole (therapeutic
drug monitoring (TDM) strongly recommended), posaconazole
(not approved for children, TDM recommended); itraconazole
(not approved for children), liposomal amphotericin B (off-
label) or micafungin. Other options against pulmonary mold
infection may include aerosolized liposomal amphotericin B
or caspofungin (off-label indication). Secondary prophylaxis is
highly recommended in patients with IFI prior to allo-HSCT.
Monitoring of Aspergillus using serum galactomannan levels
is feasible, yet the negative predictive value is relatively high
and other molds remain undetected (37). According to ECIL-
8 guidelines galactomannan monitoring is valuable in children
not receiving mold-active prophylaxis, but experts discourage its
value in those receiving mold-active prophylaxis (35).
The choice of antifungal drug during and after HSCT
should be determined by local circumstances and resistance
patterns, organ toxicity (i.e., nephrotoxicity) and drug-drug
interactions (e.g., azoles with calcineurin inhibitors) (52).
During conditioning, azoles are not recommended whereas
L-Amb (off-label) may be preferred until discharge, though
nephrotoxicity may limit its use. Triazoles incl. posaconazole
have numerous drug interactions including interaction with
calcineurin inhibitors that must be considered, and therapeutic
drug monitoring is mandatory (53). At the time of writing,
posaconazole is still not licensed for recipients <18 years in
the EU.
Prophylaxis Against Toxoplasmosis
Toxoplasmosis is a widely distributed zoonosis produced by the
parasite T. gondii and continues to be a major challenge in
the management of pediatric allogeneic HSCT recipients (54).
The incidence of toxoplasmosis varies widely due to variable
seroprevalence among patient populations, but a majority of
patients (up to 3/4) with post HSCT toxoplasmosis disease were
IgG-positive prior to HSCT, thus indicating that reactivation
plays a major role rather than de novo infection (55, 56). Most
cases of Toxoplasma are observed between 2 and 6 months
after transplant with a risk persisting across the first year of
transplant and sometimes even later. Early cases occurring
during the first 4 weeks of transplant are very rare but
have a high mortality rate. Prevention of disease by pre-
HSCT assessment of sero-positivity and either prophylaxis
with trimethoprim/sulfamethoxazole or preemptive strategy with
weekly PCR-monitoring is recommended in seropositive patients




Prior to routine Pneumocystis jirovecii pneumonia (PJP)
prophylaxis, the cumulative incidence of PJP after allo-HSCT
was estimated at 9–16%. Early mortality rates are high, and
prophylaxis is strongly recommended after engraftment until
at least day +180. Trimethoprim/sulfamethoxazole given 2–3
times weekly is the drug of choice for the primary prophylaxis
of PJP in adults and children and should be given during the
entire period at risk. All other drugs, including pentamidine,
atovaquone and dapsone, are considered second-line alternatives
when trimethoprim/sulfamethoxazole is poorly tolerated or
contraindicated and are preferred over inhaled pentamidine (57).
PJP prophylaxis is relevant in patients with delayed immune
reconstitution (CD4 T-cell < 200/µL) or patients receiving IST
for GvHD (58).
Prophylaxis Against COVID-19
The Coronavirus disease 2019 (COVID-19), caused by the
severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-
2), continues to expand worldwide, since it was declared a
pandemic by the WHO in March 2020 (59). One year later,
116 million confirmed cases and 2.6 million deaths worldwide
have been reported to WHO [World Health Organization
Coronavirus (COVID-19) Dashboard https://covid19.who.int].
A cancer diagnosis in adults doubles the risk of COVID-19-
associated intensive care unit admission and death, compared
with the general population (60, 61). Data regarding COVID-
19 in transplanted pediatric patients are very scarce. Despite
pediatric cancer patients mostly presenting with a mild or
asymptomatic course, the risk of severe COVID-19 may be
higher compared with the general pediatric population (62, 63).
The Center for International Blood and Marrow Transplant
Research (CIBMTR) recently reported a 68% survival 1 month
after COVID-19 diagnosis in 318 transplant recipients of
whom only 29 of were children, adolescents or young adults.
The mortality risk was 2.7 higher in case the infection
occurred in the first 12 months after transplant (61). Organ
toxicities induced by chemo/radiotherapy, especially in the lungs,
and risks of additional infections, due to pancytopenia and
immunosuppression, are likely to contribute to exacerbate the
COVID-19 course, even though an ultimately protective role of
immunosuppression cannot be ruled out (61).
National and local guidelines, policies and procedures should
be followed, as the COVID-19 situation varies amongst regions.
Yet, the EBMT provides guidelines on COVID precautions
in the EBMT-setting, including considerations in pediatric
HSCT (9). These guidelines are continuously updated on
the EBMT website (https://www.ebmt.org/sites/default/files/
2021-02/EBMT%20COVID-19%20guidelines%20v.%2015.02
%202021-02-18.pdf). The section dealing with prevention
policies confirms case tracking and isolation of SARS-CoV-2
infected individuals, hand hygiene, masks and social distancing
as the main prevention strategy. Furthermore, patients and
donors should be tested upon admission and/or before the
conditioning regimen starts. Visits in the outpatient setting
should be limited to patients who are in real need, whereas
long-term patients may be followed by telemedicine. The risks
associated with postponing scheduled appointments should be
balanced (59).
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TABLE 3 | Risk grouping following discharge from allogeneic hematopoietic cell
transplantation in childhood or adolescence.
Risk assessment at time of discharge, day 100, day 180
Low risk Int risk High risk
No GvHD No or controlled GvHD Active/uncontrolled GvHD
No IST Low IST Multimodal IST
No infections Recurrent infections Viral reactivations
CD4 > 200 CD4 100-200 CD4 < 100
N > 0.5 × 109/l N ≤ 0.5 × 109/l N ≤ 0.5 × 109/l
GvHD, graft vs. host disease; IST, immune suppressive therapy; CD4, CD positive
T-lymphocytes; N, neutrophil count.
Transplant deferral during the pandemic may be considered
in non-urgent patients, as hemoglobinopathies, even though a
careful evaluation of the risk-benefit balance is recommended.
In case of recipient SARS-CoV-2 positivity, transplantation
should be delayed up to two consecutive negative results, even
though persistence of virus positivity for several weeks or months
in severely immunocompromised patients is not uncommonly
reported (61). Donation from a SARS-CoV-2 positive donor
should also be deferred. Graft cryopreservation is recommended
during the peaks of the pandemic, due to travel restrictions which
may prolong its delivery time. The impact of cryopreservation
on primary and long-term engraftment is still to be assessed,
but many centers prefer mobilized peripheral blood stem cell to
ensure good counts, also after thawing, in order not to jeopardize
engraftment (60).
POST DISCHARGE PRECAUTIONS
On discharge after allo-HSCT, most patients are still severely
immune compromised. Local logistical and geographical factors
determine whether patients are discharged to their home or
to a local patient hotel or alike. In either case, individual
precautions to avoid community acquired infections during
immune reconstitution, must be taken. The considerable risk
of morbidity or mortality due to acquired infection should be
minimized by avoiding microbial exposure. However, no studies
support specific approaches of how to protect the child or young
adult from community acquired infections. Instead, a number of
observations have historically led to recommendations regarding
social distancing, food intake and exposure to indoor or outdoor
microbes (1, 7, 64–66). The scope of the precautions is to reduce
the risk of exposure to especially RSV, Influenza A, B and C,
Parainfluenza, Coronavirus, Norovirus, Rota virus, Adenovirus,
Salmonella Enteritidis, Toxoplasma and Aspergillus species and
should be comprehensive in children due to high rates of airborne
infections amongst other children below 6–8 years.
As a part of the consensus workshops, a survey demonstrated
that most centers recommend avoiding crowds during the first
year post HSCT by not attending school or kindergarten and by
avoiding public transportation etc., but the timing of return to
normal activities differs widely.
Therefore, in order to provide expert based guidelines on these
complex scenarios, we developed a schematic algorithm during
the three workshops recommending a set of minimal precautions
that should be implemented based on risk stratification of
the individual transplanted child. During the workshops we
constructed the algorithm defined by three different risk groups,
defined as low, intermediate or high risk. The risk grouping
is based on immune recovery (CD4 positive T-cells and
granulocytes), presence of GvHD, level of IST and infection
rate (recurrent viral re-activation, recurrent airway infections),
see Table 3. According to this, low risk patients are GvHD-
free, off IST, do not experience recurrent infections and CD4
counts are >200/µL. High risk group patients have uncontrolled
GvHD, receive multimodal IST, have viral reactivations or CD4
counts are <100/µL, whereas intermediate risk group are in
between. Patients may move between risk groups in the event of
occurrence/recurrence of GvHD or frequent infections.
This risk stratification can then be used to guide patients
and their families to a risk adapted set of precautions listed in
Figure 1. We suggest that such risk classification is done at three
different timepoints post HSCT: timepoint 1 at initial discharge
post-HSCT, timepoint 2 approximately day +100 and timepoint
3 at approximately day +180. At each timepoints, a patient
should be stratified according to the risk group (Table 3), which
then indicate the set of precautions that should be kept.
The precautionary measures agreed upon by the experts
during the workshops include food restrictions, social distancing
and behavior at home and outdoors. Importantly though, local
(geographical) specific circumstances and outbreaks in infection
should be considered and food restrictions may be adjusted
accordingly. In principle, the more people in a crowd the higher
the risk for transfer of airbornemicrobes. Thus, childcare centers,
indoor waterparks, malls, cinemas and public transportation
are regarded as high risk, whereas small family gatherings
or small restaurants are regarded intermediate risk. Individual
circumstances should be considered when relaxing restrictions
as a return to a more normal life may improve the general
well-being of the child.
Specific counseling of the family could according to the work
shops include:
If possible, patients should not return to a home with high
mold and re-housing should be considered until the problem is
fixed. Sharing the bedroom with sick siblings should be avoided
if possible. Furthermore, the acquisition of new pets and shifting
a cat litter box should be avoided in the early post HSCT period.
Outdoor precautions include avoiding bathing in pools and
playing in sandboxes. Bathing in the ocean is considered safe,
provided the patient has no indwelling catheters.
VACCINATIONS
Children undergoing HSCT lose immunity to vaccine-
preventable diseases and are exposed to various pathogens upon
reintegration into social life with potentially life-threatening
pneumococcal infections playing a prominent role. Thus,
early and comprehensive re-immunization is important
post-HSCT and should recognize stepwise recovery of the
immune system after HSCT and potential impact of IST for
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FIGURE 1 | Schematic algorithm for protective measures following discharge from allogeneic hematopoietic cell transplantation in childhood or adolescence. Red
color indicates not recommended, green color indicates no restrictions. High risk foods: unpasteurized milk; undercooked egg; blue cheese; honey; raw and
undercooked fish, meat and seafood; selected nuts; dried spices from uncontrolled shops/markets; unwashed or unpeeled fresh fruit, water from private wells.
Nursery: 0–3 years. Kindergarten: 3–5/6 years. High risk pets: turtles (yersinia), shifting cat trays (toxoplasma), visit stables (aspergillus), acquire new pets. Private
pool: if not at bacterial infection. Tap water: local outbreaks may moderate.
prophylaxis/treatment of GvHD that impacts immune recovery.
Considerations on the timing of re-vaccination post-HSCT
must balance the clinical demand for swift protection and
the risk of immunization failure if vaccination is given too
early. In the setting of this background an expert group of
pediatric infectious disease and transplant physicians identified
the specific clinical demand and reviewed currently available
evidence focussing on the pediatric age group and generated the
consensus recommendation detailed in Figure 2.
General Principles for Immunization
Post-HSCT in Children
Based on data from a retrospective analysis of revaccination
of pediatric HSCT recipients from Great-Britain (67), the
prospective IKAST trial on vaccination of children after HSCT
(68) and a trial on 13-valent pneumococcal conjugate vaccination
in HSCT recipients (69) the following recommendations
are made (Table 4):
– Use a fixed starting time point for re-vaccination with
the newborn DTaP/IPV/HBV/Hib combination vaccine and
the 13-valent pneumococcal conjugate (PCV13) vaccine six
months post-HSCT [if leukocyte engraftment and platelets ≥
50 × 10(9)/l] and immunize irrespective of donor/graft type,
GvHD, IST and/or measures of immune recovery.
– Use combination vaccine DTaP/IPV/HBV/Hib irrespective of
chronologic age.
– Optional/conditional vaccinations (highlighted in yellow
in Figure 2) should not interfere with evidence-based
immunizations (DTaP/IPV/HBV/Hib, PCV13) starting at 6
months. Optional/conditional vaccinations preferably start 12
months post-HSCT.
– Immunization with non-live vaccines is safe during IVIG
replacement as there is no specific risk besides non-response.
Check titres 3 months after stopping IVIG.
– Start vaccination with live vaccines (MMR-V) not earlier
than 24 months post-HSCT and restrict to immunocompetent
patients without GvHD and IST ≥ 3 months and off
IVIG substitution.
– Consider checking antibody concentrations prior and 1month
after primary series in patients with GvHD, IST, IVIG
treatment and/or delayed immune reconstitution.
Additional note: Single-center experience indicates that
providing non-live vaccines earlier than 6 months post-HSCT
may be feasible in children with very swift immune recovery.
However, there are no published data on this policy and limited
induction of immunologic memory and duration of protection
must carefully be weighed against potential earlier protection.
Specific Recommendation for Selected
Vaccines
Influenza
High risk for life-threatening influenza-virus infection post-
HSCTmandates annual immunization with inactivated influenza
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FIGURE 2 | Recommended and optional/conditional vaccinations after allogeneic hematopoietic cell transplantation in childhood. DTaP-IPV-HBV/Hib, hexavalent
diphtheria, tetanus, acellular pertussis, inactivated poliovirus, hepatitis B, Haemophilus influenzae type B vaccine; PCV13, 13-valent pneumococcal conjugate vaccine;
Men ACWY-135, quadrivalent meningococcal conjugate vaccine; Men B, recombinant meningococcal type B vaccine; PPSV23, 23-valent pneumococcal
polysaccharide vaccine; MMR-V, live attenuated measles, mumps, rubella, varicella-zoster-virus vaccine; HPV, human-papilloma-virus vaccine; TBE,
tick-born-encephalitis vaccine; HAV, hepatitis A vaccine. # start of vaccination at 3 months post-HSCT possible after individual risk-benefit analysis (please refer to
text). $ start of vaccination at 6 months post-HCT possible after individual risk-benefit analysis (please refer to text). * only immunocompetent patients post-HSCT, if ≥
3 months without immunosuppressive therapy and ≥ 3 months without active cGvHD.
vaccines comprising quadrivalent strain coverage. Two doses
should be given for first influenza vaccination post-HSCT and
after antigenic shift/drift. Live influenza vaccine is contra-
indicated post-HSCT. Starting influenza vaccination at 4 months
after transplantation may be considered in cases of influenza
pandemic or upcoming season.
Pneumococcus
PCV13 comprises the majority of pneumococcal serotypes
detected in invasive pneumococcal disease post-HSCT.
Administration of the 23-valent pneumococcal polysaccharide
vaccine (PPSV23) at 24 months may broaden protection.
However, sparse data on the immunogenicity of PPV23 with
regard to serotypes reaching beyond PCV13 result in an optional
recommendation for PPSV23 post-HSCT.
Meningococcus
No data exist on the specific risk for invasive meningococcal
disease post-HSCT but immunecompromised patients represent
candidates for meningococcal vaccination. Clinical relevant
protection requires vaccination with both A/C/W/Y135
conjugate and recombinant MenB vaccines. Only few
disappointing data are available for A/C/W/Y135 conjugate
and no data with MenB vaccination post-HSCT resulting in
an optional recommendation for meningococcal vaccination
starting at 12 months post-HSCT.
Human Papilloma Virus
Profound risk of HPV-associated squamous cell carcinoma exists
post-HSCT and most European countries recommend universal
HPV vaccination. Consequently, all adolescent transplant
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TABLE 4 | Recommendations on specific vaccines following allogeneic hematopoietic cell transplantation in childhood.




Hexavalent diphtheria, tetanus, acellular pertussis, inactivated
poliovirus, Hepatitis B, Haemophilus influenzae type B vaccine
(DTaP-IPV-HBV/Hib)
6 4 0-1-2-12
13-valent pneumococcal conjugate vaccine (PCV13) 6 4 0-1-2-12 PCV13 comprises most serotypes in invasive pneumococcal
disease post-HSCT
Quadrivalent, inactivated influenza virus vaccine (comprehensive
current seasonal strain coverage)
(4-)6 1-2 0-2 For first vaccination post-HSCT or after substantial antigenic
shift/drift two doses should be given. Yearly revaccination is
recommended. Early start at 4 months post-HSCT is possible in
case of pandemia or up-coming influenza season. Live influenza
vaccine is contra-indicated in HSCT recipients.
Live, attenuated measles- mumps-rubella virus vaccine (MMR) 24 2 0-2 If immunocompetent (≥ 3 months without
GvHD/immunosuppression)
Conditional vaccinations
Human papilloma virus vaccine (HPV) 12 3 0-2-8 Substantial risk for HPV-related cancer post-HSCT. Vaccination of
both boys and girls if age ≥ 9years
Hepatitis A vaccine (HAV) 12 2 0-6 If risk of exposure
Tick-borne encephalitis vaccine (TBE) 12 3 0-2-8 If living in endemic region
Optional vaccinations
Live, attenuated varicella-zoster-virus vaccine (in combination with
MMR; MMR-V)
24 2 0−2 If immunocompetent (≥ 3 months without GvHD or
immunosuppression. VZV-reactivations frequently occur before 24
months and are thus beyond effect of the live vaccine which can
only be administered from 24 months post-HSCT.
Quadrivalent meningococcal type A,C,W,Y-135 conjugate vaccine
(Men ACWY-135)
12 3 0-2-8 No data on specific risk of invasive meningococcal disease
post-HSCT. Few and disappointing data for tetra-valent conjugate
vaccine post-HSCT.
Recombinant meningococcal type B vaccine (Men B) 12 3 0-2-8 No reported experience with MenB vaccination after HSCT.
23-valent pneumococcal polysaccharide vaccine (PPSV23) 24 1 n/a PPSV23 may broaden serotype protection. Sparse data on the
immunogenicity of PPSV23 with regard to the serotypes beyond
PCV13.
*Months from HSCT.
**Months from start of vaccination.
recipients should receive HPV vaccination starting from 12
months post-HSCT.
Varicella-Zoster-Virus
High incidence of VZV reactivations with substantial morbidity
exists in the first 2 years post-HSCT. Only few case-series report
on the use of the live-attenuated VZV vaccine in pediatric
HSCT recipients. Immunization can only be instituted at 2
years after HSCT coming too late to prevent the major burden
of VZV reactivation. These considerations lead to an optional
recommendation for immunization with live-attenuated VZV
vaccine in immunocompetent children at least 24 months post-
HSCT. Vaccination of family members and household contacts
is urgently recommended. If a post-vaccination rash develops
the vaccinated should avoid contact with HSCT recipients who
may receive aciclovir prophylaxis. Non-live VZV vaccines have
recently been investigated in immunocompromised hosts. An
inactivated VZV vaccine as well as an adjuvanted VZV subunit
vaccine prevented zoster reactivation in adult autologous HSCT
recipients. No data are available for either of these vaccines in the
post-HSCT setting. Thus, no recommendation can be made for
their use in children post-HSCT.
COVID-19
During the COVID-19 pandemic, it seems prudent to administer
COVID-19 vaccines—under the condition that they are non-live
and non-replicating—to all recipients of allogeneic HSCT, as
soon and as far as they are available for use in children and
adolescents (of note: the Pfizer/BioNTec COVID-19 vaccine
label includes adolescents 12 years or older). Nevertheless,
clinical trials are going on to assess safety and efficacy also in
younger patients. In analogy with the recommendation for the
influenza vaccination, in the current active pandemic situation,
the immunization may be started earlier than 6 months after
alloHSCT e.g., at 3 months - but it is recommended to do
antibody assessments whenever available prior to and 4 weeks
after (last) vaccination of the primary series in order to assess
immunogenicity as information on this is lacking, in particular
in the setting of pediatric alloSCT. This recommendation is in
accordance with the current EBMT guideline for COVID-19
vaccination in allogeneic HSCT recipients (https://www.ebmt.
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org/sites/default/files/2021-02/COVID%20vaccine%20version
%204.03%20with%20table.pdf).
More extensive data on the rationale and risk-benefit
assessment for specific vaccines can be found in two international
consensus documents on vaccination in HSCT recipients
(70, 71).
CONCLUSIVE REMARKS
The emergence and rapid worldwide spread of SARS-COV-2
during early 2020 had substantial impact on general health
care and for children and adolescents with the need for
allogeneic HSCT it exposed the necessity of strict infection
prevention measures. Restrictions regarding hospital resources,
donor availability, issues with logistics of stem cell product
transport as well as potential consequences of COVID-19
exposure of donors and patients are among the long list of
factors potentially impacting provision of care. Nevertheless,
the reported incidence of COVID-19 cases among pediatric
HSCT recipients is low thus far, which may at least partially
reflect the comprehensive measures for social distancing
which are implemented as routine standard-of-care in the
majority of pediatric HSCT centers. Thus, adherence to the
recommendations for preventing infections outlined in this
manuscript are considered of particular importance in general
but also in the current COVID-19 era.
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